Compare Fortinet Inc (FTNT) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Zoetis Inc — how do they compare? Fortinet Inc trades at $194.7 (market cap $138.75B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Fortinet Inc is far larger — about 4.6× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Zoetis Inc for 70 Days on average.
| FTNT | ZTS | |
|---|---|---|
Market Cap | $138.75B | $30.20B |
Volume | 2,956,908 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $191.27 | $147.53 |
52-Week Low | $75.23 | $69.09 |
Typical Hold Time | 72 Days | 70 Days |
Enterprise Value | $135.17B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $194.75, up 2.89% today and near its 52-week high of $203. The stock shows strong bullish momentum with consistent earnings beats (Q1-Q2 2026) and robust revenue growth from $4.4B in 2022 to $6.8B in 2025. Technical indicators signal bullish moving averages but overbought RSI levels. The company maintains exceptional profitability with 80.2% gross margins and 28.17% net income margins, though valuation multiples remain elevated with P/E at 66.82.
Outlook remains positive driven by cybersecurity demand and AI security tailwinds, with 2026 revenue guidance of $7.5B. Key risks include high valuation sensitivity and competitive pressures. Analyst consensus is mixed (42% Buy, 49% Hold) with $158.64 price target below current levels, suggesting cautious optimism amid strong fundamentals.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
